Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Mouse hybridomas producing antibodies against structural proteins of mumps virus were established by fusion of FO or SP 2/0 myeloma cells with spleen cells from BALB/c mice immunized with purified preparations of egg-grown mumps virus. Ascites fluids collected after i.p. inoculation of mice were characterized by different serologic tests. By immune precipitation tests with [35S]methionine-labeled mumps virus polypeptides, 17 clones were found to produce antibodies against the nucleocapsid protein (NP), 11 against the polymerase (P) protein, 10 against the membrane (M) protein, 12 against the fusion (F) protein, and 24 against the hemagglutinin-neuraminidase (HN) protein. Competitive binding enzyme-linked immunosorbent assay (ELISA) tests were performed to determine the reactivity of the monoclonal antibodies with different antigenic sites of each structural component. The monoclonal antibodies directed against the NP, P, and M proteins identified a minimum of 10, 10, and 9 separate antigenic sites, respectively. The 12 clones directed against F were directed against a minimum of eight separate antigenic determinants. These antibodies did not neutralize the infectivity of the virus either in the absence or presence of anti-gamma-globulin. Only low capacity to block hemolysis (HL) activity of the virus was detected in clones directed against three of the eight antigenic sites. Based on their serologic reactivity, the 24 clones directed against the HN protein could be divided into four groups. The first group of clones could not inhibit any biologic activity of the protein. The second group consisted of two clones that blocked HL but did not block hemagglutination (HA) or neuraminidase (NA) activity. The third group, which included five clones, blocked HA, NA, and HL activity of the virus and had high neutralizing capacity. These clones were directed against three distinct antigenic sites. Two of the clones directed against one antigenic site could block NA activity only when a large substrate, fetuin, was used, but not when a small substrate, neuraminlactose, was used in the test. The fourth group included five clones that could block NA but not HA activity of the virus. These clones could neutralize the infectivity of the virus and had high capacity to block HL activity. In blocking experiments, all these antibodies reacted with one antigenic site. The reaction of all clones was tested in ELISA with four different strains of mumps virus. Each strain had unique antigenic sites. Variations were found in four, three, and three different antigenic sites of the NP, P, and HN proteins, respectively.
 ...
PMID:The reactions of monoclonal antibodies with structural proteins of mumps virus. 620 53

The results of screening for antibodies against rubella, morbilli, mumps, herpes simplex, rota and Epstein-Barr virus in serum from patients with multiple myeloma are reported. Antibodies against herpes simplex virus were found in all samples, present in high titres in most samples. Antibody titres against the other five viruses were generally low. A possible association of common virus infections and myelomatosis is discussed.
 ...
PMID:Antibodies to common viruses in sera from patients with multiple myeloma. 630 Dec 12

Mumps virus is a common infectious agent of humans, causing parotitis, meningitis, encephalitis, and orchitis. Like other paramyxoviruses in the genus Rubulavirus, mumps virus catalyzes the proteasomal degradation of cellular STAT1 protein, a means for escaping antiviral responses initiated by alpha/beta and gamma interferons. We demonstrate that mumps virus also eliminates cellular STAT3, a protein that mediates transcriptional responses to cytokines, growth factors, nonreceptor tyrosine kinases, and a variety of oncogenic stimuli. STAT1 and STAT3 are independently targeted by a single mumps virus protein, called V, that assembles STAT-directed ubiquitylation complexes from cellular components, including STAT1, STAT2, STAT3, DDB1, and Cullin4A. Consequently, mumps virus V protein prevents responses to interleukin-6 and v-Src signals and can induce apoptosis in STAT3-dependent multiple myeloma cells and transformed murine fibroblasts. These findings demonstrate a unique cytokine and oncogene evasion property of mumps virus that provides a molecular basis for its observed oncolytic properties.
 ...
PMID:STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. 1274 96

Whereas patients with multiple myeloma (MM) have a well-documented susceptibility to infections, this has been less studied in other B-cell disorders, such as Waldenstrom's macroglobulinemia (WM) and monoclonal gammopathy of undetermined significance (MGUS). We investigated the humoral immunity to 24 different pathogens in elderly patients with MM (n = 25), WM (n = 16), and MGUS (n = 18) and in age-matched controls (n = 20). Antibody titers against pneumococci, staphylococcal alpha-toxin, tetanus and diphtheria toxoids, and varicella, mumps, and rubella viruses were most depressed in MM patients, next to lowest in WM and MGUS patients, and highest in the controls. In contrast, levels of antibodies specific for staphylococcal teichoic acid, Moraxella catarrhalis, candida, aspergillus, and measles virus were similarly decreased in MM and MGUS patients. Comparable titers in all study groups were seen against Haemophilus influenzae type b (Hib), borrelia, toxoplasma, and members of the herpesvirus family. Finally, a uniform lack of antibodies was noted against Streptococcus pyogenes, salmonella, yersinia, brucella, francisella, and herpes simplex virus type 2. To conclude, although MM patients displayed the most depressed humoral immunity, significantly decreased antibody levels were also evident in patients with WM and MGUS, particularly against Staphylococcus aureus, pneumococci, and varicella. Conversely, immunity was retained for Hib and certain herpesviruses in all study groups.
 ...
PMID:Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. 2150 64

Attenuated live virus vaccinations are generally recommended 24 months following hematopoietic cell transplantation (HCT) in patients not receiving immunosuppressive therapy. To date, there are no data regarding the safety of live-attenuated herpes zoster or measles-mumps-rubella (MMR) vaccinations in multiple myeloma patients on maintenance lenalidomide or bortezomib following autologous HCT. One hundred thirty-seven multiple myeloma patients on maintenance lenalidomide or bortezomib post-auto-HCT who received either MMR or herpes zoster vaccine were analyzed and any adverse events documented in the medical record in the 42 days following vaccination were recorded. Patients were vaccinated a median of 25 months (range, 18-62) post transplant. The most common post-vaccination adverse event was upper respiratory tract infection (18/137 patients); no rash attributed to vaccine strains or other adverse outcomes potentially related to the vaccines were identified. MMR and herpes zoster vaccination were safe and well-tolerated in this cohort.
 ...
PMID:Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. 2942 30

Common childhood infectious diseases have been associated with a reduced risk of following haematopoietic malignancies, but investigations on multiple myeloma (MM) are scarce. Information about 213 MM cases and 1128 healthy controls were obtained from a multicentre population-based Italian case-control study. The association between chickenpox, measles, mumps, pertussis and rubella and the MM risk was estimated by unconditional logistic regression, adjusting for age, gender and residence area. No association was found between MM risk and any considered infectious disease. The number of infections was slightly inversely associated with the risk of MM, but statistical significance was not reached (OR 0.87, 95% CI 0.55-1.4 for 1-2 diseases vs. none and OR 0.68, 95% CI 0.41-1.1 for 3-5 diseases, respectively, P = 0.131). We did not find a clear evidence that common infections during childhood are associated with the subsequent risk of developing MM.
 ...
PMID:Childhood infectious diseases and risk of multiple myeloma: an analysis of the Italian multicentre case-control study. 2984 44